China Resources Pharmaceutical Group Limited (HKG:3320)
Hong Kong · Delayed Price · Currency is HKD 5.64
+0.31 (5.82%)
At close: Mar 27, 2026
HKG:3320 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 269,574 | 257,673 | 244,704 | 218,183 | 192,920 | |
Revenue Growth (YoY) | 4.62% | 5.30% | 12.16% | 13.10% | 14.31% |
Cost of Revenue | 225,066 | 216,984 | 206,366 | 184,564 | 164,096 |
Gross Profit | 44,508 | 40,689 | 38,337 | 33,619 | 28,823 |
Selling, General & Admin | 29,185 | 26,556 | 25,262 | 21,999 | 19,383 |
Other Operating Expenses | 2,675 | 2,148 | 2,044 | 1,878 | 1,422 |
Operating Expenses | 31,860 | 28,704 | 27,306 | 23,878 | 20,805 |
Operating Income | 12,648 | 11,985 | 11,031 | 9,741 | 8,019 |
Interest Expense | -2,013 | -2,262 | -2,363 | -2,428 | -2,209 |
Interest & Investment Income | 483.97 | 681.1 | 587.69 | 721.18 | 595.97 |
Earnings From Equity Investments | 261.96 | 368.01 | 417.11 | 332.34 | 255.48 |
Other Non Operating Income (Expenses) | 1,157 | 1,007 | 1,057 | 181.76 | 287.98 |
EBT Excluding Unusual Items | 12,538 | 11,779 | 10,731 | 8,549 | 6,950 |
Merger & Restructuring Charges | - | -1.18 | - | - | -7.02 |
Impairment of Goodwill | -185.6 | -92.23 | -82.81 | -85.14 | -100.82 |
Gain (Loss) on Sale of Investments | -320.25 | -720.41 | -220.69 | -166.16 | 101.66 |
Gain (Loss) on Sale of Assets | 43.11 | 70.12 | 63.85 | 334.84 | 7.83 |
Asset Writedown | -280.04 | -178.87 | -611.12 | -271.11 | -115.43 |
Other Unusual Items | 0.51 | 73.27 | - | - | 14.22 |
Pretax Income | 11,796 | 10,930 | 9,880 | 8,361 | 6,850 |
Income Tax Expense | 2,143 | 2,527 | 2,105 | 1,703 | 1,435 |
Earnings From Continuing Operations | 9,653 | 8,403 | 7,775 | 6,658 | 5,415 |
Minority Interest in Earnings | -5,608 | -5,052 | -3,921 | -3,158 | -2,345 |
Net Income | 4,045 | 3,351 | 3,854 | 3,500 | 3,070 |
Preferred Dividends & Other Adjustments | 3.36 | 19.59 | - | - | - |
Net Income to Common | 4,042 | 3,331 | 3,854 | 3,500 | 3,070 |
Net Income Growth | 20.73% | -13.06% | 10.11% | 14.00% | 10.59% |
Shares Outstanding (Basic) | 6,283 | 6,283 | 6,283 | 6,283 | 6,283 |
Shares Outstanding (Diluted) | 6,283 | 6,283 | 6,283 | 6,283 | 6,283 |
Shares Change (YoY) | - | - | - | - | -0.01% |
EPS (Basic) | 0.64 | 0.53 | 0.61 | 0.56 | 0.49 |
EPS (Diluted) | 0.64 | 0.53 | 0.61 | 0.56 | 0.49 |
EPS Growth | 21.34% | -13.57% | 10.11% | 14.00% | 10.60% |
Free Cash Flow | - | 14,891 | 13,027 | 8,542 | 8,495 |
Free Cash Flow Per Share | - | 2.37 | 2.07 | 1.36 | 1.35 |
Dividend Per Share | 0.194 | 0.135 | 0.154 | 0.142 | 0.122 |
Dividend Growth | 43.70% | -12.34% | 8.81% | 15.82% | 20.94% |
Gross Margin | 16.51% | 15.79% | 15.67% | 15.41% | 14.94% |
Operating Margin | 4.69% | 4.65% | 4.51% | 4.46% | 4.16% |
Profit Margin | 1.50% | 1.29% | 1.57% | 1.60% | 1.59% |
Free Cash Flow Margin | - | 5.78% | 5.32% | 3.91% | 4.40% |
EBITDA | 15,300 | 14,637 | 13,570 | 11,688 | 9,732 |
EBITDA Margin | 5.68% | 5.68% | 5.54% | 5.36% | 5.04% |
D&A For EBITDA | 2,652 | 2,652 | 2,539 | 1,947 | 1,713 |
EBIT | 12,648 | 11,985 | 11,031 | 9,741 | 8,019 |
EBIT Margin | 4.69% | 4.65% | 4.51% | 4.46% | 4.16% |
Effective Tax Rate | 18.17% | 23.12% | 21.31% | 20.37% | 20.94% |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.